MedTrace Logo

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

NCT00709683 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 216

Last updated 2016-03-07

No results posted yet for this study

Summary

This study is conducted in Africa. The aim of this observational study is to evaluate the incidence of adverse events while using NovoMix® 30 FlexPen® under normal clinical practice conditions.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Tunisia

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709683 on ClinicalTrials.gov